Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    06-September-2000      
Issue 146 Next Update - 14:00 UTC 08:00 EST    07-September-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Proceed To Article In Today's Vidyya
pollution
Parkinson's Disease is more than a brain ailment.


Proceed To Article More Than Just a Brain Disorder - Parkinson's Disease
For many years, researchers have known that the movement problems associated with Parkinson's disease result from a loss of neurons that produce a nerve-signaling chemical called dopamine in one part of the brain. A new study suggests that Parkinson's disease (PD) also affects nerve endings that produce a related chemical, norepinephrine, in the heart. The finding improves understanding about how Parkinson's disease develops and may lead to a way of predicting the disorder and possibly even preventing it. More...

Proceed To Article Fact Sheet - Parkinson's Disease
Parkinson's disease belongs to a group of conditions called motor system disorders. Parkinson's and related disorders are the result of the loss of dopamine-producing brain cells. Dopamine is a chemical messenger responsible for transmitting signals within the brain. Parkinson's disease occurs when certain nerve cells, or neurons, die or become impaired. More...

Proceed To Article Scientists Group Together To Create A Virtual Cell
In an effort to "glue" together large groups of scientists pursuing some of the biggest unsolved problems in biomedicine today, the National Institute of General Medical Sciences has provided $5 million for the first of five years to a consortium of basic scientists called the Alliance for Cellular Signaling (AFCS). NIGMS anticipates spending a projected total of $25 million on the project over the course of five years. More...

Proceed To Article AstraZeneca Receives FDA Approval To Market Atacand HCT ®
AstraZeneca announced today the approval of Atacand HCT ® (candesartan cilexetil- hydrochlorothiazide) by the U.S. Food and Drug Administration (FDA) for second-line treatment of hypertension. Atacand HCT combines the angiotensin II receptor blocker (ARB) Atacand ® with the diuretic hydrochlorothiazide providing physicians with another treatment option for those patients who are unable to control their hypertension with a single agent. More...

Proceed To Article

Yellow Fever Spreads To Sierre Leone, WHO Continues To Fight Lassa Fever
The World Health Organization said Tuesday that officials in Sierra Leone have been put on alert to prevent a yellow fever epidemic in neighboring Liberia spreading across the border. A 4-year-old child was thought to have arrived from Sierra Leone with the disease, but died before that could be confirmed, WHO said. More...


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.